
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT
- About
Bright Minds Biosciences Inc (DRUG)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: DRUG (3-star) is a STRONG-BUY. BUY since 14 days. Profits (25.63%). Updated daily EoD!
1 Year Target Price $94.01
1 Year Target Price $94.01
4 | Strong Buy |
2 | Buy |
0 | Hold |
0 | Sell |
0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 2231.48% | Avg. Invested days 37 | Today’s Advisory Strong Buy |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 308.95M USD | Price to earnings Ratio - | 1Y Target Price 94.01 |
Price to earnings Ratio - | 1Y Target Price 94.01 | ||
Volume (30-day avg) 6 | Beta 0.17 | 52 Weeks Range 0.94 - 79.02 | Updated Date 08/15/2025 |
52 Weeks Range 0.94 - 79.02 | Updated Date 08/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.4 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -10.57% | Return on Equity (TTM) -11.21% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 268250896 | Price to Sales(TTM) - |
Enterprise Value 268250896 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -0.07 | Shares Outstanding 7083240 | Shares Floating 2983319 |
Shares Outstanding 7083240 | Shares Floating 2983319 | ||
Percent Insiders 22.42 | Percent Institutions 78.63 |
Upturn AI SWOT
Bright Minds Biosciences Inc
Company Overview
History and Background
Bright Minds Biosciences Inc. was founded in 2019 and is focused on developing novel therapeutics for neuropsychiatric disorders, epilepsy, and pain. The company is developing a portfolio of next-generation serotonin 5-HT2C receptor agonists.
Core Business Areas
- Drug Development: Bright Minds focuses on developing and commercializing novel small molecule therapeutics for neurological and psychiatric disorders with unmet medical needs, with a focus on 5-HT2C receptor agonists.
- Research and Development: The company's R&D efforts are centered on preclinical and clinical studies of its drug candidates.
Leadership and Structure
Ian McDonald serves as the CEO. The company has a scientific advisory board comprising experts in neuroscience and drug development.
Top Products and Market Share
Key Offerings
- BMB-101: BMB-101, Bright Minds' lead product candidate, is a selective 5-HT2C receptor agonist being developed for Dravet Syndrome and other treatment-resistant epilepsies. Currently in preclinical development. Market share data is not yet available, it is under development. Competitors include other anti-epileptic medications such as Epidiolex (GWPH) and various other therapies from companies such as Zogenix (acquired by UCB).
- BMB-202: BMB-202, Bright Mindsu2019 investigational compound, designed to activate the 5-HT2C receptor. It is under development to potentially address the high unmet medical need in patients suffering from neuropsychiatric disorders and is currently in preclinical development. Market share data is not yet available, it is under development. Competitors include established antipsychotics and antidepressants from companies like Eli Lilly (LLY) and Pfizer (PFE).
Market Dynamics
Industry Overview
The pharmaceutical industry is competitive, with ongoing research into new treatments for neurological and psychiatric disorders. Advances in neuroscience are driving the development of more targeted therapies.
Positioning
Bright Minds is positioned as a company developing next-generation therapies focusing on 5-HT2C receptor modulation. Their competitive advantage lies in their selective agonist approach.
Total Addressable Market (TAM)
The TAM for neuropsychiatric disorders and epilepsy treatments is estimated to be in the billions of dollars. Bright Minds targets specific patient populations with unmet needs, which makes TAM more targeted.
Upturn SWOT Analysis
Strengths
- Novel therapeutic approach
- Experienced management team
- Focus on unmet medical needs
- Strong patent portfolio (pending)
Weaknesses
- Limited financial resources
- Early-stage clinical development
- High regulatory risk
- Dependence on key personnel
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion into new indications
- Positive clinical trial results
- Orphan drug designation
Threats
- Competition from established therapies
- Clinical trial failures
- Regulatory hurdles
- Generic entry upon patent expiry
Competitors and Market Share
Key Competitors
- GWPH (now UCB)
- LLY
- PFE
Competitive Landscape
Bright Minds competes with established pharmaceutical companies that have existing therapies for neurological and psychiatric disorders. Bright Minds' advantage lies in its targeted 5-HT2C agonist approach, but disadvantages include its small size and early stage of development.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by preclinical development and securing funding.
Future Projections: Future growth depends on the successful completion of clinical trials and potential commercialization or licensing agreements. Analyst estimates are limited due to the early-stage nature of the company.
Recent Initiatives: Recent initiatives include advancing BMB-101 and BMB-202 into clinical trials and exploring potential partnerships.
Summary
Bright Minds Biosciences is an early-stage pharmaceutical company focused on developing novel therapies. It has a promising technology with its selective 5-HT2C receptor agonists. However, it faces several challenges, including limited financial resources, clinical trial risks, and competition from established companies. The company's success hinges on positive clinical trial results and strategic partnerships.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Bright Minds Biosciences Inc. Investor Relations
- Company Press Releases
- SEC Filings
Disclaimers:
This analysis is for informational purposes only and does not constitute investment advice. Market share data is based on estimates and may not be precise. Financial data is limited due to the company's early-stage development. The AI rating is based on a limited understanding of the company and should not be used as the sole decision-making factor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Bright Minds Biosciences Inc
Exchange NASDAQ | Headquaters New York, NY, United States | ||
IPO Launch date 2021-03-22 | Co-Founder, CEO, President & Director Mr. Ian McDonald | ||
Sector Healthcare | Industry Biotechnology | Full time employees - | Website https://brightmindsbio.com |
Full time employees - | Website https://brightmindsbio.com |
Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio of selective 5-HT receptor agonists includes 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry; and BMB-101 which completes phase 1 trial for undisclosed seizure disorder. The company also develops BMB-201 and BMB-202 for the treatment of neuropsychiatry and neurology indications. Bright Minds Biosciences Inc. has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. The company was founded in 2017 and is headquartered in New York, New York.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.